晚期胃癌免疫治疗研究进展  

Advances on immunotherapy for late-stage gastric cancer

作　　者：周志军 徐岩 金芳[2,3] 赖淑蓉 张常华[4,5] 彭建军 何裕隆[2,3,4,5] ZHOU Zhi-jun;XU Yan;JIN Fang(The Universityof Oklahoma Health Sciences Center,Oklahoma City,Oklahoma,United States;不详)

机构地区：[1]美国俄克拉荷马大学健康科学中心,俄克拉荷马州俄克拉荷马城 [2]中山大学附属第一医院胃肠外科中心,广东广州510080 [3]中山大学胃癌诊治研究中心,广东广州510080 [4]中山大学附属第七医院消化医学中心,广东深圳518107 [5]广东省消化系统恶性肿瘤防治研究重点实验室,广东深圳518107

出　　处：《中国实用外科杂志》2022年第12期1421-1427,共7页Chinese Journal of Practical Surgery

基　　金：国家自然科学基金面上项目(No.82073148);广东省消化系统恶性肿瘤防治研究重点实验室(No.2021B1212040006);广东省自然科学基金(No.2018A030313543);深圳市“医疗卫生三名工程”资助项目(No.SZSM201911010);深圳市可持续发展科技专项(No.KCXFZ202002011010593);深圳市医学重点学科(No.SZXK016)。

摘　　要：晚期胃癌病人初诊时失去了根治性手术机会。对于此类病人,治疗方式有限,传统的治疗方式以化疗为主,联合靶向治疗。尽管如此,晚期胃癌病人的预后仍不理想。免疫治疗在部分肿瘤病人中可取得不错的疗效,能给部分病人带来长期生存获益。免疫检查点抑制剂在晚期胃癌一线和后线治疗中均展现出了较传统治疗更优的疗效,近期几项关于晚期胃癌免疫治疗的多中心随机对照Ⅲ期研究取得了令人振奋的结果,改写了晚期胃癌的治疗模式。免疫治疗策略的不断发展,必将进一步改善胃癌治疗效果。Patients with late-stage gastric cancer lost the opportunity of radical resection at the time of diagnosis.For these patients,treatment options are limited.Traditional treatment is mainly chemotherapy in combination with targeted therapy.Nonetheless,the prognosis of these patients is dismal.The emerging immunotherapy in recent years,especially immune checkpoint inhibitors(ICIs),showed an impressive responses in a subset of patients,and even brought long-term survival for some patients.Immunotherapy showed better treatment outcomes than traditional therapies such as first-line and multiple-line treatment for late-stage gastric cancer.Recently,several phase 3 multicenter randomized clinical trials showed promising results of immunotherapy in late-stage gastric cancer,which has shifted the treatment paradigm of gastric cancer.The development of novel immunotherapy strategies will further improve the treatment outcomes for these patients.

关 键 词：晚期胃癌 免疫治疗 

分 类 号：R6[医药卫生—外科学]